Roberto Spreafico, PhDSenior Director, AI-Assisted Drug Discovery at Absci Corporation
Roberto Spreafico has 15 years of experience in computational immunology, including post-doctoral training at UCLA's Institute for Quantitative and Computational Biosciences. His publications have been cited over 5,000 times. He joined Absci in May 2021 to lead the AI-assisted antibody optimization program. Previously, he worked for several biotech and pharmaceutical companies, including Synthetic Genomics, Vir Biotechnology and GlaxoSmithKline. At Vir Biotechnology, he was computational lead for the development of Sotrovimab, a best-in-class COVID-19 mAb. Thanks to his broad expertise and training, he is particularly effective in bridging machine learning, experimental data generation and NGS/bioinformatics.